In the Spotlight...
Integration of donor microbiota following FMT correlates with anti-PD-1 response in melanoma
Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes
Previous Digests
Unraveling the role of CCR1 in tumor myeloid cells
June 10, 2026
Pancreatic cancer (PDA) is a highly resistant and difficult-to-treat tumor type, often marked by extensive fibroinflammatory stroma and infiltration of immunosuppressive myeloid cells. These myeloid cells, including macrophages and granulocytes, have been noted to have high expression of CCR1...
AI reads between the sequences to decode TCR specificity
June 3, 2026
Predicting TCR recognition from sequence alone is challenging because TCRs with low sequence similarity may bind the same peptide–MHC (pMHC), whereas nearly identical TCR sequences may bind different pMHCs. Wang, Yeh, et al. developed a new approach to map...
Yin and Yang of tumoral NK cells: cytotoxic and suppressive phenotypes uncovered
May 19, 2026
NK cells are promising targets for cancer immunotherapy, but clinical results have so far been limited. Therefore, there is a need to better understand NK cell subphenotypes and their function in tumors. Two recent papers characterized tumoral NK cells...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
